Efficacy and safety of roflumilast cream 0.3% in patients with chronic plaque psoriasis: pooled PASI and PASI-HD results from the DERMIS-1 and DERMIS-2 Phase 3 Trials

被引：0

作者：

Papp, Kim ^{[1
,2
]}

Lebwohl, Mark ^{[3
]}

Hong, H. Chih-ho ^{[1
,4
]}

Kircik, Leon ^{[5
,6
]}

Pariser, David ^{[7
,8
]}

Strober, Bruce ^{[9
,10
]}

Krueger, Gerald ^{[11
]}

Krupa, David ^{[12
]}

Burnett, Patrick ^{[12
]}

Berk, David ^{[12
]}

Higham, Robert ^{[12
]}

机构：

[1] Probity Med Res, Waterloo, ON, Canada

[2] K Papp Clin Res, Waterloo, ON, Canada

[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[4] Univ British Columbia, Dept Dermatol & Skin Sci, Vancouver, BC, Canada

[5] Physicians Skin Care PLLC, Indiana Med Ctr, Louisville, KY USA

[6] Skin Sci PLLC, Indiana Med Ctr, Louisville, KY USA

[7] Eastern Virginia Med Sch, Norfolk, VA USA

[8] Virginia Clin Res Inc, Norfolk, VA USA

[9] Yale Univ, Sch Med, New Haven, CT 06520 USA

[10] Cent Connecticut Dermatol, Cromwell, CT USA

[11] Univ Utah Hlth, Salt Lake City, UT USA

[12] Arcutis Biotherapeut Inc, Westlake Village, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：AB156 / AB156

页数：1